Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin

Ryan D. Cassaday, David I. Marks, Daniel J. DeAngelo, Elias J. Jabbour, Anjali S. Advani, Susan O'Brien, Tao Wang, Alexander Neuhof, Erik Vandendries, Hagop M. Kantarjian, Wendy Stock, Matthias Stelljes

Research output: Contribution to journalLetterpeer-review

4 Scopus citations
Original languageEnglish (US)
Pages (from-to)e77-e81
JournalBritish Journal of Haematology
Volume191
Issue number3
DOIs
StatePublished - Nov 1 2020

Keywords

  • HSCT
  • acute lymphoblastic leukaemia
  • inotuzumab ozogamicin
  • relapsed
  • treatment cycles

ASJC Scopus subject areas

  • Hematology

Cite this